

643671

DAVIES COLLISON CAVE

Level 10, 10 Barrack Street, SYDNEY NSW 2000, AUSTRALIA
TELEPHONE: (02) 262 2611 FACSIMILE: (02) 262 1080
PATENT OFFICE SPEED DIAL: 510

Our Ref: 351717

P/00/008
Section 29(1)
Regulation 3.1(2)

AUSTRALIA

Patents Act 1990

NOTICE OF ENTITLEMENT

SCHERING AKTIENGESELLSCHAFT, of Postfach 65 03 11, D-1000 Berlin 65, Germany, the applicant in respect of Application No 45114/89 state the following:

- 1 The Nominated Person is entitled to the grant of a patent in respect of the application because the said Nominated Person derived title to the invention from the said inventors by employment contract.
- 2 The Nominated Person is entitled to claim priority from the application listed in the declaration under Article 8 of the PCT because the Nominated Person either made the application or has entitlement from the applicants in respect of the application listed in the declaration under Article 8 of the PCT, and because the application is the first application made in a convention country in respect of the invention.

DATED this 20th day of September 1993.

SCHERING AKTIENGESELLSCHAFT
By their Patent Attorneys
DAVIES COLLISON CAVE

Peter Stearne

DR PETER A STEARNE




AU8945114

(12) PATENT ABRIDGMENT (11) Document No. AU-B-45114/89
 (19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 643671

- (54) Title
 14ALPHA,17ALPHA-ETHANO-ESTRATRIENES
- International Patent Classification(s)
 (51)⁵ C07J 053/00 A61K 031/56
- (21) Application No. : 45114/89 (22) Application Date : 10.11.89
- (87) PCT Publication Number : WO90/05139
- (30) Priority Data
- (31) Number (32) Date (33) Country
 3838779 11.11.88 DE GERMANY
- (43) Publication Date : 28.05.90
- (44) Publication Date of Accepted Application : 25.11.93
- (71) Applicant(s)
 SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN
- (72) Inventor(s)
 GERALD KIRSCH; HENRY LAURENT; RUDOLF WIECHERT; SYBILLE BEIER; WALTER ELGER;
 JAMES R. BULL; GUNTHER NEEF
- (74) Attorney or Agent
 DAVIES COLLISON CAVE, GPO Box 3876, SYDNEY NSW 2001
- (56) Prior Art Documents
 AU 77571/87 C07J 053/00
- (57) Claim

1. 14alpha,17alpha-Ethanoestratrienes of general formula I




(I).

in which

R¹ means a hydrogen atom, an alkyl or acyl group with 1 to 12 carbon atoms,

R² means a hydrogen atom or a methyl group,

R³ means a hydrogen atom or an acyl group with 1 to 12 carbon atoms and




and R^4 is an alpha- or beta-position alkyl radical with 1 to 8 carbon atoms or an alpha,beta-alkenyl radical or an alpha,beta-alkynyl radical, optionally exhibiting several double bonds, both radicals with 2 to 8 carbon atoms.

5. A method of fertility control of women, comprising administering thereto an effective amount of a compound according to claim 1 or claim 2 either alone or together with a pharmaceutically acceptable diluent or carrier.

6. A method of treatment of estrogen deficiency symptoms of women, comprising administering thereto an effective amount of a compound according to claim 1 or claim 2 either alone or together with a pharmaceutically acceptable diluent or carrier.

7. Compounds of formula IV



in which

R^2 stands for a hydrogen atom or a methyl group and either X means an

alpha-position carbaldehyde group $\cdots \text{C} \begin{matrix} \text{H} \\ \diagup \\ \text{=O} \end{matrix}$ and

A-B means a C-C single bond as well as E-F means a C-C double bond or C-C single bond,

or

X means a beta-position carbaldehyde group $-\text{C} \begin{matrix} \text{H} \\ \diagup \\ \text{=O} \end{matrix}$ and

A-B and E-F mean two C-C double bonds or two single bonds.

OPI DATE 28/05/90


APPLN. ID 45114 / 89

AOJP DATE 05/07/90


PCT NUMBER PCT/DE89/00712

PCTINTERNATIONALE ANMELDUNG VERÖFFENTLICHT NACH DEM VERTRAG ÜBER DIE
INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT)


(51) Internationale Patentklassifikation 5 : C07J 53/00, A61K 31/56	A1	(11) Internationale Veröffentlichungsnummer: WO 90/05139 (43) Internationales Veröffentlichungsdatum: 17. Mai 1990 (17.05.90)
(21) Internationales Aktenzeichen: PCT/DE89/00712 (22) Internationales Anmeldedatum: 10. November 1989 (10.11.89) (30) Prioritätsdaten: P 38 38 779.4 11. November 1988 (11.11.88) DE (71) Anmelder (für alle Bestimmungsstaaten ausser US): SCHE- RING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN [DE/DE]; Müllerstr. 170/178, D-1000 Berlin 65 (DE). (72) Erfinder; und (75) Erfinder/Anmelder (nur für US) : KIRSCH, Gerald [DE/ DE]; Luciusstr. 6b, D-1000 Berlin 33 (DE). LAURENT, Henry [DE/DE]; Glambeker Weg 21, D-1000 Berlin 28 (DE). WIECHERT, Rudolf [DE/DE]; Petzower Str. 8a, D-1000 Berlin 39 (DE). BEIER, Sybille [DE/DE]; Uh- landstr. 121, D-1000 Berlin 15 (DE). ELGER, Walter [DE/DE]; Schorlemer Allee 12B, D-1000 Berlin 33 (DE). BULL, James, R. [ZA/ZA]; 342 Ridgeview Road, Waterkloof Ridge 2, 0001 Pretoria (ZA). NEEF, Günther [DE/DE]; Markgraf-Albrecht-Straße 4, D-1000 Berlin 15 (DE).	(81) Bestimmungsstaaten: AU, DK, FI, HU, JP, NO, US. Veröffentlicht <i>Mit internationalem Recherchenbericht.</i> 643671	

(54) Title: 14 α ,17 α -ETHANO-ESTRATRIENES(54) Bezeichnung: 14 α ,17 α -ETHANO-ESTRATRIENE


(I).



(a)



(II)



(III)

(57) Abstract


New 14 α ,17 α -ethano-estratrienes of general formula (I) wherein R¹ is a hydrogen atom, an alkyl or acyl group with 1 to 12 carbon atoms, R² is a hydrogen atom or a methyl group, R³ is a hydrogen atom or an acyl group with 1 to 12 carbon atoms and (a) is either (II) or (III), where R⁴ is an alkyl residue in the α or β position with 1 to 8 carbon atoms or an α,β -alkenyl residue which may contain several double bonds or an α,β -alkinyl residue, both with 2 to 8 carbon atoms, are described. Also described is a process for producing them. These new compounds have a marked oestrogenic activity.

(57) Zusammenfassung

Es werden neue 14 α ,17 α -Ethano-estratriene der allgemeinen Formel (I), worin R¹ ein Wasserstoffatom, eine Alkyl- oder Acylgruppe mit 1 bis 12 Kohlenstoffatomen, R² ein Wasserstoffatom oder eine Methylgruppe, R³ ein Wasserstoffatom oder eine Acylgruppe mit 1 bis 12 Kohlenstoffatomen und (a) entweder (II) oder (III), wobei R⁴ ein α - oder β -ständiger Alkylrest mit 1 bis 8 Kohlenstoffatomen oder ein gegebenenfalls mehrere Doppelbindungen aufweisender α,β -Alkenyl- oder ein α,β -Alkinylrest, beide mit 2 bis 8 Kohlenstoffatomen, ist, bedeuten, beschrieben sowie ein Verfahren zu deren Herstellung. Die neuen Verbindungen besitzen starke östrogene Wirksamkeit.

14alpha,17alpha-Ethanoestratrienes

This invention relates to 14alpha,17alpha-ethanoestratrienes of general formula I




in which

R¹ means a hydrogen atom, an alkyl or acyl group with 1 to 12 carbon atoms,

R^2 means a hydrogen atom or a methyl group,

R³ means a hydrogen atom or an acyl group with 1 to 12 carbon atoms and



and R⁴ is an alpha- or beta-position alkyl radical with 1 to 8 carbon atoms or an alpha,beta-alkenyl radical or an alpha,beta-alkinyl radical, optionally exhibiting several double bonds, both radicals with 2 to 8 carbon atoms.

Further, the invention relates to a process for the production of compounds of general formula I, pharmaceutical preparations, which contain compounds of general formula I as



well as the use of the compounds according to the invention for fertility control of women as well as for treatment of estrogen deficiency symptoms of women.

As acyl groups R^1 and R^3 , radicals of organic carboxylic acids with 1 to 12 carbon atoms are suitable. They are derived from aliphatic, cycloaliphatic, aliphatic-cycloaliphatic, cycloaliphatic-aliphatic and aromatic and aromatic-aliphatic monocarboxylic acids, preferably those acids that are derived from hydrocarbons. The number of carbon atoms in the cycloaliphatics varies from 3 to 7, the phenyl as well as the naphthyl radical can be mentioned as aromatics.


As radicals R^1 and R^3 for the acyl groups the acetic, propionic, butyric, isobutyric, pivalic, caproic, acrylic, crotonic, heptylic, caprylic, pelargonic, decanoic, undecanoic, dodecanoic, 3-cyclopentylpropionic and benzoic acid are preferred.

If R^1 stands for an alkyl group, in this case alkyl radicals, optionally with one or more unsaturations, with 1 to 12 carbon atoms are suitable. R^1 can thus be an alkyl, alkenyl or alkinyl radical with up to 12 carbon atoms. Especially to be mentioned are all alkyl radicals corresponding to the acyl groups mentioned for R^1 and R^3 . The methyl group is especially preferred.

A hydrogen atom is the preferred radical for R^2 .

For the fragment  there can stand either a C15-C16

double bond or a C15-C16 alkylene group



which


is substituted in the 16 position with an alpha- or beta-position ^{containing from 1 to 8 carbon atoms,} alkyl radical, or an optionally repeatedly unsaturated alk-1,2-enyl radical ^{having} ~~with 1 to 8 or~~ 2 to 8 carbon atoms. They are especially the methyl, ethyl, propyl, isopropyl, propenyl, butyl, t-butyl, butadienyl, cyclopentylmethyl and cyclopentylmethylene as well as the hexyl group, of which the methyl group can be mentioned as preferred.

Finally a straight-chain alk-1,2-ynyl group with 2 to 8 carbon atoms is suitable as substituent R⁴. The ethynyl and ^{propynyl} ~~propionyl~~ group are preferred.


14alpha,17alpha-etheno-bridged steroids are described in J. Chem. Soc., Chem. Commun., 1986, 451-453 and 14alpha,17alpha-etheno-bridged and 14alpha,17alpha-ethano-bridged steroids in international patent application PCT/DE87/00361 as the compounds coming closest to the compounds of the general formula I, with the same substituents in 3 and 17 position as the compounds according to the invention; in 13 position the known compounds exhibit a methyl group. While the compounds of general formula I present here exhibit the C15-C16 double bond or the alkyl radical on the C-16 atom in the upper ring of the steroid skeleton, the C15-C16 double bond, or the C-16 alkyl substituent in/on the lower D ring of the steroid skeleton is in the same arrangement (in each case beta) of the 17 OR substituent (R = H, acyl). In other




words, with the present compounds of formula I 14alpha,17alpha-ethanoestratrienes (A) or 14alpha,17alpha-ethano-16-alkyl-estratrienes (B) are involved, while with the already known compounds 14alpha,17alpha-ethenoestratrienes (C) or 14alpha,17alpha-alkylethano estratrienes (D) are involved:




(A)



(B)



(C)



(D)

Further, from PCT/DE87/00361 it comes out that the 14alpha,17alpha-ethenoestratrienes of type C can be hydrogenated to the also strongly estrogen-effective corresponding 15,16-dihydro-compounds.

Like the compounds belonging to the prior art, the compounds according to the invention are distinguished by an extraordinarily strong estrogenic effectiveness. In the Allen-Doisy test after subcutaneous administration they are as strongly estrogenically effective as ethinylestradiol and of comparable effectiveness as the already known compounds of type (C).

In the Allen-Doisy test, an evaluation of vaginal smears in ovariectomized rats is performed on days 3, 4, 5 and 8 after the single administration of the test substance. The following cycle stages are distinguished:

- 1= diestrus (leukocytes and nucleated epithelial cells),
- 2= proestrus (nucleated epithelial cells),
- 3= estrus (denucleated horny plaques),
- 4= metestrus (denucleated horny plaques, leukocytes, epithelial cells).

After oral or subcutaneous administration, estrogenically effective substances result in the proliferation of the vaginal epithelium and in the cornification of surface cell layers. That amount of an estrogen is considered as a threshold value, at which 50% of the animals reach stage 3.

The results of the Allen-Doisy test with 14alpha,17alpha-ethano-1,3,5(10),15-estratetraene-3,17beta-diol as test compound as well as 14alpha,17alpha-ethano-1,3,5(10)estratriene-3,17beta-diol and estradiol as comparison compounds are summarized in table 1. The uterus weights are determined after autopsy of those animals on which vaginal smears had previously been made.

Table 1

Vaginal smear test according to Allen and Doisy (A 1.1 modified) on rats with s.c. administration.
 Injection: 1X on d1; autopsy c5, n=6 /group;
 control n = 12

Treatment		Difference body weight		Uterus weight				Uterus weight (mg)/100g kg				Smears expos. / n, trt.
		d5 - d1 (g)		(moist) 1)		(dry) 1)		(moist)		(dry)		
		Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
14alpha,17alpha-ethano-1,3,5(10), 15-estratriene-3, 17beta-diol	/ 3,00 ug	-0.33	3.56	713.92	360.43	135.83	54.62	335.57	156.29	64.61	23.10	6 / 6
	/ 1,00 ug	6.50	2.59	415.62	250.80	77.23	37.73	199.21	129.50	36.92	19.64	6 / 6
	/ 0,30 ug	11.50	2.26	238.45	25.65	44.93	3.84	110.19	14.62	20.74	2.21	6 / 6
	/ 0,10 ug	16.50	6.98	156.62	10.85	29.23	2.76	70.72	6.58	13.22	1.70	6 / 6
	/ 0,03 ug	18.17	4.75	128.07	17.22	25.38	5.28	58.89	6.68	11.65	2.17	0 / 6
14alpha,17alpha-ethano-1,3,5(10), 15-estratetraene-3, 17beta-diol	/ 3,00 ug	0.67	6.06	576.37	248.15	92.98	21.53	276.18	113.26	44.81	10.05	6 / 6
	/ 1,00 ug	2.83	4.83	322.72	37.87	66.87	13.52	158.32	23.83	32.38	7.77	6 / 6
	/ 0,30 ug	11.33	3.56	299.50	71.34	45.72	6.04	135.06	34.94	20.50	2.28	6 / 6
	/ 0,10 ug	10.83	2.79	191.80	105.71	28.18	5.62	89.92	51.58	13.14	2.58	5 / 6
	/ 0,03 ug	17.33	3.72	134.80	41.83	24.18	3.13	60.90	22.05	10.83	1.51	2 / 6
estradiol	/ 3,00 ug	7.67	5.28	367.28	108.65	71.65	14.70	170.30	49.06	33.38	7.18	6 / 5
	/ 1,00 ug	5.17	2.23	234.77	21.88	59.55	19.30	111.65	9.93	28.42	9.49	6 / 6
	/ 0,30 ug	12.00	2.10	192.10	40.03	42.18	17.18	89.32	18.90	19.57	8.01	6 / 6
	/ 0,10 ug	14.33	3.56	137.05	17.94	25.07	3.50	61.85	9.30	11.27	1.44	6 / 6
	/ 0,03 ug	20.17	4.75	123.17	13.29	23.60	4.98	54.05	5.67	10.52	2.32	0 / 6
Control		21.08	4.25	123.72	20.19	27.58	6.09	54.20	11.27	17.09	3.11	0 / 12

(M ± SD----p less than 0.05 vs. control, LSD -- test)
 As other compounds, 14alpha,17alpha-ethano-1,3,5(10)-estratriene-16alpha-ethinyl-3,17beta-diol was tested;
 at a dose of 0.3 micrograms/d s.c. all 6 examined animals show positive smears.

It is surprising that the compounds according to the invention, which contain no 17alpha-ethinyl group, are at least as effective as ethinylestradiol. Ethinylestradiol is still the most often used estrogen in oral treatment.

In comparison with ethinylestradiol, the compounds according to the invention offer the advantage that they exhibit no ^{17alpha-ethinyl}~~17beta-hydroxy~~ group, which could cause undesirable metabolic reactions.

As is still to be explained, moreover they can be produced by a substantially simpler process than the structurally close compounds of type (C).

Thus, the invention also relates to compounds of general formula I for use in the treatment of estrogen deficiency symptoms and for fertility control in women.

The compounds according to the invention can be formulated and used in the same way as ethinylestradiol. They are processed according to methods known in the art into the usual pharmaceutical agent forms with the additives, vehicles and/or taste corrigents usual in galenic pharmacy. For oral administration, tablets, coated tablets, capsules, pills, suspensions or solutions are especially suitable. For parenteral administration, oily solutions, such as, for example, sesame oil or castor oil solutions, are especially suitable, which can optionally contain in addition another diluent, such as, for example, benzyl benzoate or benzyl alcohol.


The active ingredient concentration in the pharmaceutical compositions is dependent on the form of administration and the



field of use. Thus, for example, for the treatment of estrogen deficiency symptoms, capsules or tablets can contain 0.001 to 0.05 mg of active ingredient, oily solutions for intramuscular injection per 1 ml approximately 0.01 to 0.1 mg of active ingredient and vaginal ointments about 0.1 to 10 mg per 100 ml of ointment. For contraception in women, the estrogens according to the invention can be used in combination with gestagens. Tablets or coated tablets for daily intake of a tablet or a coated tablet are to contain preferably 0.003 to 0.05 mg of the estrogen according to the invention and 0.05 to 0.5 mg of a gestagen.


The compounds according to the invention can be used in the case of estrogen deficiency symptoms of women, such as, for example, amenorrhea, dysmenorrhea, sterility, frigidity, endometritis, colpitis and menopausal symptoms. Further, the compounds can be used as estrogenic components in compound preparations with gestagens for fertility control in women.

The new compounds of general formula I




(1).

in which R^1 , R^2 and R^3 and $\begin{array}{c} \text{A} \\ | \\ \text{B} \end{array}$ have the meaning already indicated, are produced so that




a compound of general formula IIIa



(IIIa).

in which

R^2 has the meaning indicated in formula I is first hydrogenated and then decarboxylated and oxidized to a compound of general formula II'a




(II'a)

b) or if




stands for



with R^{4b}


meaning a methyl group,

a compound of general formula IIIb



(IIIb).

in which R^2 has the meaning already indicated, is reduced to a compound of general formula II'b




(II'b)

c) or if




stands for

with R^{4c} meaning


an alkyl radical or an alpha,beta-alkenyl radical, both with 2 to 8 carbon atoms, optionally exhibiting several double bonds

a compound of general formula IIIc



(IIIc).


in which R^2 has the meaning already indicated, is reacted with an appropriate Wittig reagent to a compound of general formula II''c



(II'c).

in which R^{4c} represents an alpha,beta-alkenyl radical, with 2-8 carbon atoms, optionally exhibiting several double bonds


the compound of general formula II''c optionally is hydrogenated to a compound of general formula II'c




(II'c).

in which $R^{4c'}$ represents an alkyl radical with 2 to 8 carbon atoms,

d) or if




stands for




with R^{4d}

meaning an alpha,beta-alkinyl radical with 2 to 8 carbon atoms, a compound of general formula III c




(IIIc)

is reacted in a modified Wittig reaction with a mixture of triphenylphosphane and tetrahalomethane CHal_4 , and Hal can be bromine and iodine, preferably bromine, to a compound of general formula II''d



and then in a compound of one of general formulas II'a, II'b, II''c, II''c or II''d optionally the 3-methyl ether is cleaved and if the process variant d) is present, after conversion of the compound of general formula II''d or the corresponding 3-hydroxy compound by cleavage of HHal with a base and halogen/hydrogen exchange and optionally after coupling of the resulting H-ethynyl compound with a linear alkylation reagent exhibiting 1 to 6 carbon atoms to a compound of general formula II'd




in which R^{4d} has the meaning already indicated and then optionally the released 3-hydroxy group is again etherified and/or the 17-acetoxy group is saponified, optionally the 3-and

17-hydroxy groups are again esterified and optionally a 3,17-diacetyloxy compound thus obtained is selectively saponified to the 3-hydroxy-17-acyloxy compound.


Depending on which intermediate or end product of general formulas II'a, II'b, II''c, II'c or II''d (the compounds of these formulas can also be end products of general formula I, if R^1 is to be a methyl group and R^3 is to be an acetyl group) is desired, different procedures according to the invention are necessary.

a) The D ring is to exhibit a C15-C16 double bond: starting from a 16 α -carbaldehyde of general formula IVa




(IVa),

in which R^2 stands for an H atom or a methyl group, by oxidation of the carbonyl group, for example with Jones reagent (chromium(VI) oxide/sulfuric acid), the corresponding carboxyl group IIIa is produced.



(IIIa)

By hydrogenation of the 14 α ,17 α -etheno bridge, decarboxylation and oxidation (introduction of the C15-C16 double bond) IIIa is converted into a compound of general formula II'a.




(II'a)

The decarboxylation and oxidation are performed by heating in a solvent under the action of at least one oxidation agent, for example with lead tetraacetate and copper(II) acetate hydrate in benzene or toluene.


b) The D ring is to have a C-16 alpha- or beta-methyl group:

a compound of general formula IIIc




(IIIc).

in which R² stands for an H atom or a methyl group and the aldehyde function can be in the alpha or beta position, by reaction with 1,2-dimercaptoethane is converted in its ethylene-1,2-dithioketal derivative IIIb;



(IIIb)

this compound of formula IIIb is then reduced with a protic solvent to a compound of general formula II'b



(II'b)


for example, with Raney nickel in alcohol.

c) The D ring is to carry a C16-alpha or beta-alkyl or C-16alpha- or beta-alkenyl radical, with 2 to 8 carbon atoms, optionally exhibiting several double bonds:


also starting from an aldehyde of general formula IIIc by a C-C linkage reaction the 16alpha or 16beta-alkenyl or alkyl side chain is synthesized, for example, by Wittig reaction of IIIc with a suitable Wittig reagent, i.e., with a Wittig reagent poorer by one C atom than R^{4c} .

The double bond resulting in the C16 side chain by the Wittig reaction (as well as optionally present in other double bonds) can optionally be again eliminated by hydrogenation.

By the variant described under c) there are achieved both compounds of general formula II''C



in which $R^{4c''}$ represents at least one simply unsaturated alkenyl radical with 2 to 8 carbon atoms and compounds of general formula II'c




in which now in $R^{4c'}$ the double bonds which were present in $R^{4c''}$ are hydrogenated.

d) The D ring is to exhibit a straight-chain C16 alpha- or C16 beta-alk-1,2-ynyl radical with 2 to 8 carbon atoms as substituent:

An aldehyde of formula IIIc as starting product is reacted in a modified Wittig reaction with a mixture of triphenylphosphine and tetrabromomethane or tetraiodomethane. In this case, triphenyl-dibromo (or diiodo) methylene phosphorane functions as reactive species. Then hydrogen bromide or hydrogen iodide is then eliminated from the resulting Wittig reaction

product of general formula II'd with a base, such as, for example, *n*-butyllithium. In the aqueous working up of the reaction product obtained after the elimination, the corresponding 16 alpha- or 16 beta-ethinyl compound is obtained; if after dehydrohalogenation an *n*-alkylation reagent with 1 to 6 carbon atoms in the alkyl radical is added, compounds of general formula II'd are achieved, in which R⁴ is an alpha- or beta-position alk-1,2-ynyl radical with 3 to 8 carbon atoms. Thus, for example, working up in the presence of methyl iodide leads to the corresponding 16-prop-1,2-ynyl compound.

This invention also relates to the compounds of formula IV



(IV).

in which

R² stands for a hydrogen atom or a methyl group and either


X means an alpha-position carbaldehyde group $\cdots\cdots\text{C}\begin{matrix} \text{H} \\ \diagup \\ \text{=O} \end{matrix}$ and

A-B means a C-C single bond as well as E-F means a C-C double bond or C-C single bond,
or


X means a beta-position carbaldehyde group $\text{---}\text{C}\begin{matrix} \text{H} \\ \diagup \\ \text{=O} \end{matrix}$ and

A-B and E-F mean two C-C double bonds or two single bonds, since these compounds represent valuable and variously usable intermediate products because of the chemically versatile keto group.


The production of the compounds of general formula IV takes place starting from 3-methoxy-1,3,5(10),14,16-estrapentaen-17-yl acetate ($R^2=H$)



[G. H. Rasmusson et al., Steroids 22, 107, (1973)] or starting from 3-methoxy-1,3,5(10),14,16-estrapentaene-18-methyl-17-yl acetate ($R^2=CH_3$) by reaction with an unsaturated aldehyde in vicinal position to the keto group. Instructions for preparation of the last-named compound are found in example 16. For example, reaction of the first compound ($R^2=H$) with acrolein in the cold and in the presence of a Lewis acid yields the [4+2] cyclo adduct




with alpha-position aldehyde function on the C16 atom, while the [4+2] cyclo adduct with beta-position aldehyde function on the en



the C16 atom is formed with propinal in the heat. Both cyclo adducts can be catalytically hydrogenated, for example with palladium-activated carbon (also if $R^2=CH_3$).

Thus the compounds of general formula I according to the invention are distinguished especially by their high estrogenic effectiveness, and they can in addition be produced according to a relatively simple process and easily by the compounds of general formula IVa or IIIC.

The known 14alpha,17alpha-etheno-1,3,5(10)-estratrienes (C) so far have been produced by reduction of the corresponding 16-phenyl sulfones of formula



in which

$R^{1a} = R^1$ and $R^{3a} = R^3$ or mean precursors of R^1 or R^3 , with an excess of 6% sodium amalgam (J. Chem. Soc., Chem. Commun. 1986, 451-453). For example, for reductive elimination of the phenyl sulfone groups from 2 g of 14alpha,17alpha-etheno-3-methoxy-16alpha-phenylsulfonyl-1,3,5(10)-estratrien-17beta-ol acetate in the usual way 31.5 g of 6% sodium amalgam is necessary, which contains almost 30 g of mercury. For reasons of economy and because of the extreme toxicity of the mercury, such a synthesis cannot be transferred on a reasonable technical

scale, since, for example, to reduce 100 kg of the above-named sulfone, 1.5 tons of mercury would be necessary. On the other hand, the present process avoids these disadvantages and damages that occur in dealing with mercury.

Moreover, the compounds of general formula I according to the invention, in which



stands for a C15-C16 double

bond, as shown in example 15, can be hydrogenated, by which identical 15,16-dihydro compounds are achieved as by hydrogenation of the known 14alpha,17alpha-ethenoestratrienes of type C.

This invention is explained in greater detail by the following examples.

Example 1

17beta-Acetoxy-14alpha,17alpha-etheno-3-methoxy-1,3,5(10)-estratriene-16alpha-carbaldehyde (2)

20.0 g (30.8 mmol) of 3-methoxy-1,3,5(10),14,16-estra-pentaen-17-yl acetate (1) [G. H. Rasmusson et al., Steroids 22, 107, (1973)] and 4.17 ml (62.7 mmol) of acrolein in 124 ml of toluene were mixed by instillation with ice cooling with 0.19 ml (1.6 mmol) of boron trifluoride etherate in 11.4 ml of toluene. The reaction was stirred for 16 hours at room temperature and then poured onto ice/water. Then it was extracted with ethyl acetate and the organic phase, after washing with sodium bicarbonate solution and water, was dried on sodium sulfate. Filtration and evaporation of the solvent yielded 9.9 g of solid residue. By chromatography on silica gel with ethyl acetate/hexane (1:2 $\longrightarrow$ 1:1), 8.55 g of (2) with a melting point of 183-185°C was obtained.

$$[\alpha]_D^{20} + 102.5^\circ \text{ (C 0.120, CHCl}_3\text{)}$$

Example 2

17beta-Acetoxy-14alpha,17alpha-etheno-3-methoxy-1,3,5(10)-estratriene-16alpha-carboxylic acid (3)

8.0 g (21.0 mmol) of 2 in 180 ml of acetone was mixed by instillation with 11.0 ml (29.3 mmol) of Jones reagents (2.67 g of chromium(VI) oxide in 7.7 ml of water and 2.3 ml conc. sulfuric acid) at 0°C. The reaction mixture was stirred for 3 1/2 hours with ice cooling and 1 hour at room temperature and

then poured onto ice/water. Then it was extracted with ethyl acetate, the organic phase was washed with water and dried on sodium sulfate. Filtration and removal of solvent yielded 8.03 g of (3) with a melting point of 194-198°C.

Example 3

17beta-Acetoxy-14alpha,17alpha-ethano-3-methoxy-1,3,5(10)-estratriene-16alpha-carboxylic acid (4)

8.0 g of (3) was hydrogenated in 672 ml of ethanol in the presence of 1.76 g of Pd-C (10%) at standard pressure. After filtration and evaporation of the solvent, 7.5 g of (4) was obtained as crude product with a melting point of 224-227°C.

Example 4

14alpha,17alpha-Ethano-3-methoxy-1,3,5(10),15-estratetraen-17beta-ol acetate (5)

7.45 g (18.7 mmol) of (4) and 0.65 (3.26 mmol) of copper(II) acetate hydrate were stirred in 1.5 ml of pyridine and 137 ml of benzene first for 30 minutes at room temperature and after addition of 13.5 g (30.4 mmol) of lead tetraacetate at 90°C were stirred for 4 hours in a nitrogen atmosphere with exclusion of light. The reaction mixture was filtered through silica gel, rewashed with 2 liters of ethyl acetate/hexane (1:1) and the filtrate was concentrated by evaporation. By chromatography of the oily residue on silica gel with ethyl acetate/hexane (1:1),

1.27 g of (5) was obtained as bright yellow oil, additionally 1.16 g was contaminated.

Example 5

14alpha,17alpha-Ethano-1,3,5(10),15-estratetraene-3,17beta-diol
(6)

1.18 g (3.35 mmol) of (5) in 354 ml of toluene was refluxed with 88.5 ml (106.2 mmol) of diisobutylaluminium hydride (1.2 molar in toluene) for 14 hours in a nitrogen atmosphere. The cooled reaction mixture was poured on ice/dilute acetic acid. Then it was extracted with ethyl acetate and the organic phase, after washing with sodium bicarbonate solution and water, was dried on sodium sulfate. After filtration and evaporation of the solvent, 1.3 g of solid was obtained, which after chromatography on silica gel with hexane ---- hexane/ethyl acetate (1:1) yielded 540 mg of (6) with a melting point of 200°C.

$[\alpha]_D^{20} - 11.4^\circ$ (c 0.105 CHCl₃).

Example 6

17beta-Acetoxy-14alpha,17alpha-ethano-3-methoxy-1,3,5(10)-estratriene-16alpha-carbaldehyde (7)

2.0 g of (2) in 250 ml of ethyl acetate was hydrogenated with 0.5 g of Pd-C (10%) at standard pressure. After removal of the catalyst and evaporation of the solvent, 1.99 g of (7) with a melting point of 151-152°C was obtained.

Example 7

16alpha-(1,3-Dithiolan-2-yl)-14alpha,17alpha-ethano-3-methoxy-1,3,5(10)-estratrien-17beta-ol acetate (8)

6.51 g (17.0 mmol) of (7) and 2.26 ml (26.9 mmol) of 1,2-dimercaptoethane were dissolved in 15 ml of methylene chloride and mixed with instillation at 0°C with 0.6 ml (4.76 mmol) of boron trifluoride etherate in 5.9 ml of methylene chloride at 0°C. The reaction mixture was stirred for 3 more hours at room temperature, diluted with ethyl acetate and washed with 5% sodium hydroxide solution and water. Drying of the organic phase on sodium sulfate, filtration and evaporation of the solvent yielded 7.62 g of crude product of (8), which is used for Raney nickel desulfurization.

Example 8

14alpha,17alpha-Ethano-3-methoxy-1,3,5(10)-estratriene-16alpha-methyl-17beta-ol acetate (9)

7.52 g of (8) was refluxed in 400 ml of ethanol together with about 15 g of Raney nickel in a nitrogen atmosphere. After filtration and removal of the solvent 5.60 g of (9) with a melting point of 115°C was obtained.

Example 9

14alpha,17alpha-Ethano-16alpha-methyl-1,3,5(10)-escratriene-3,17beta-diol (10)

2.0 g (5.42 mmol) of (9) was refluxed with 75.0 ml (91.4 mmol) of diisobutylaluminum hydride (1.2 molar in toluene) for 5 1/2 hours under nitrogen. The cooled reaction mixture was diluted with toluene and poured onto ice/dilute acetic acid. After addition of common salt, it was extracted with ethyl acetate and the organic phase was washed with sodium bicarbonate solution and water. After drying on sodium sulfate, filtration and after removal of the solvent, 1.71 g of solid was obtained. Recrystallization in acetone/hexane yielded 610 mg of (10) with a melting point of 264-265°C.

$$[\alpha]_D^{20} +30.4^{\circ} (C 0.105; CHCl_3).$$

Example 10

17beta-Acetoxy-14alpha,17alpha-etheno-3-methoxy-1,3,5(10),15-estratetraene-16-carbaldehyde (11)

10.0 g (30.8 mmol) of (1) and 28.21 g of a mixture of propinal, 2-butanone and diethyl ether [produced according to M.G. Valiev et. al. Synthesis 461 (1960); batch: 36.5 g (0.65 mmol) of propargyl alcohol; the product after working up according to instructions still contains 2-butanone and diethyl ether] in 114 ml of toluene were refluxed for 10 hours. The cooled reaction mixture was concentrated by evaporation (15.57 g

of crystallizing oil) and recrystallized in ethyl acetate/hexane. 7.84 g of (11) with a melting point of 155.5°C was obtained.

$[\alpha]_D^{20} -52.3^\circ$ (C 0.105; CHCl₃)

Example 11

17beta-Acetoxy-14alpha,17alpha-ethano-3-methoxy-1,3,5(10)-estratriene-16beta-carbaldehyde (12)

2.0 g of (11) was hydrogenated with 400 mg of Pd-C (10%) in 40 ml of ethyl acetate at standard pressure. After filtration and removal of the solvent, 2.06 g of solid remained.. The crude product -- according to ¹H-NMR consisting of 85% 16beta- and 15% 16alpha-carbaldehyde -- is used for thioketalation.

Example 12

16beta-(1,3-Dithiolan-2-yl)-14alpha,17alpha-ethano-3-methoxy-1,3,5(10)-estratrien-17beta-ol acetate (13)

3.0 g (7.84 mmol) of (12) and 1.04 ml (12.4 mmol) of 1,2-dimercaptoethane are dissolved in 7 ml of methylene chloride and mixed by instillation at 0°C with 0.28 ml (2.20 mmol) of boron trifluoride etherate in 2.7 ml of methylene chloride. The reaction mixture was stirred for 20 minutes at 0°C and 3 hours at room temperature. After dilution with ethyl acetate, the reaction mixture was washed with 5% sodium hydroxide solution and water. The organic phase was dried on sodium sulfate, filtered and evaporated to dryness. 3.06 g of (13) was obtained as crude product, which was used for Raney nickel desulfurization.

Example 13


14alpha,17alpha-Ethano-3-methoxy-1,3,5(10)-estratriene-16beta-methyl-17beta-ol acetate (14)

3.0 g of (13) was refluxed together with about 7.5 g of Raney nickel in 200 ml of ethanol under protective gas. After cooling, filtration and evaporation of the solvent, 2.40 g of colorless oil was obtained, which then is reacted with diisobutylaluminum hydride.

Example 14

14alpha,17alpha-Ethano-16beta-methyl-1,3,5(10)-estratriene-3,17beta-diol (15)

2.22 g (6.02 mmol) of (14) was refluxed with 84.4 ml (101.2 mmol) of diisobutylaluminum hydride (1.2 molar in toluene) for 5 hours under inert gas. The reaction mixture was worked up analogously to (10). After drying, 1.70 g of solid was obtained, which after chromatography on silica gel with toluene → toluene/ethyl acetate (4:1) yielded 355 mg of (15) with a melting point of 233°C.

**Example 15**

14alpha,17alpha-Ethano-1,3,5(10)-estratriene-3,17beta-diol (16)

200 mg (0.675 mmol) of (6) in 25 ml of ethanol was hydrogenated in the presence of 50 mg of Pd-C (10%) at standard pressure. After filtration and evaporation of the solvent, 200

mg of (16) with a melting point of 227-230°C was obtained as crude product.

Example 16

17beta-Acetoxy-16alpha-(2,2-dibromovinyl)-14alpha,17alpha-ethano-3-methoxy-1,3,5(10)-estratriene (17)

18.9 g of carbon tetrabromide is added at -10°C to 7.3 g of 7 and 30.0 g of triphenylphosphine in 583 ml of methylene chloride. The reaction mixture is stirred for 2 more hours at -10°C and then washed with sodium bicarbonate solution and water. The organic phase is dried on sodium sulfate, filtered and concentrated by evaporation. Filtration of the solid residue (46.3 g) with ethyl acetate/hexane (1:3) through silica gel yields 9.8 g of 17 as crystallizing oil.

Example 17

17beta-Acetoxy-16alpha-(2,2-dibromovinyl)-14alpha,17alpha-ethano-3-methoxy-1,3,5(10)-estratrien-3-ol (18)

38.1 ml of a 1 molar solution of boron tribromide in methylene chloride is instilled at -35°C in 9.5 g of 17 in 229 ml of methylene chloride. After 4 hours stirring at 0°C the reaction mixture is mixed with ice water and with methylene chloride. The organic phase is washed with water and dried on sodium sulfate. After filtration and removal of the solvent, 9.2 g of 18 is obtained as bright yellow foam.

Example 18**16alpha-Ethinyl-14alpha,17alpha-ethano-1,3,5(10)-estratriene-3,17beta-diol (19)**

4.0 g of 18 in 73 ml of tetrahydrofuran is mixed with instillation at -78°C under nitrogen with 28.6 ml of a 1.6 molar solution of butyllithium in tetrahydrofuran. After 3.5 hours stirring at -78°C 100 ml of saturated ammonium chloride solution is added to the reaction mixture. After heating to room temperature it is extracted with ethyl acetate and the organic phase is washed with water. After drying on sodium sulfate, filtration and evaporation of the solvent, 3. g of solid accumulates, which after chromatography on silica gel with ethyl acetate/hexane (1:2) yields 1.4 g of solid. After recrystallization in isopropanol 380 mg of 19 with a melting point of $226-228^{\circ}\text{C}$ is obtained.


Example 19**3-Methoxy-1,3,5(10),14,16-estra-pentaene-18-methyl-17-yl acetate**

2.5 g of 18beta-ethyl-3-methoxygona-1,3,5(10),14-tetraen-17-one (produced according to US patent 3,577,410) and 1.0 g of p-toluenesulfonic acid anhydride are refluxed in a mixture of 25 ml of acetic anhydride and 25 ml of isopropenyl acetate for 8 hours. For working up, the reaction mixture obtained was poured into ice water and then pyridine was added. It was stirred for 2 more hours, taken up in ethyl acetate, washed neutral with sodium bicarbonate and common salt solution and dried on sodium sulfate.

Removal of the solvent in a vacuum yielded 2.4 g of crude product, whose further purification [HPLC, reversed phase, 600 ml column, eluent hexane/ethyl acetate (0→30% ethyl acetate)] yielded 800 mg of the title compound with a melting point of 120°C.

Claims

1. 14alpha,17alpha-Ethanoestratrienes of general formula I




(I).

in which

R^1 means a hydrogen atom, an alkyl or acyl group with 1 to 12 carbon atoms,

R^2 means a hydrogen atom or a methyl group,

R^3 means a hydrogen atom or an acyl group with 1 to 12 carbon atoms and



and R^4 is an alpha- or beta-position alkyl radical with 1 to 8 carbon atoms or an alpha,beta-alkenyl radical or an alpha,beta-alkinyl radical, optionally exhibiting several double bonds, both radicals with 2 to 8 carbon atoms.

2. 14alpha,17alpha-ethano-1,3,5(10),15-estratetraene-3-17beta-diol;

14alpha,17alpha-ethano-16alpha-methyl-1,3,5(10)-estratriene-3,17beta-diol;

14alpha,17alpha-ethano-16beta-methyl-1,3,5(10)-estratriene-3,17beta-diol;


14alpha,17alpha-ethano-3-methoxy-1,3,5(10),15-estratetraen-17beta-ol acetate;

14alpha,17alpha-ethano-3-methoxy-1,3,5(10)-estratriene-16alpha-methyl-17beta-ol acetate;

14alpha,17alpha-ethano-3-methoxy-1,3,5(10)-estratriene-16beta-methyl-17beta-ol acetate and


16alpha-ethinyl-14alpha,17alpha-ethano-1,3,5(10)-estratriene-3,17beta-diol.

3. Process for the production of compounds of general formula I




(I).

in which R^1 , R^2 and R^3 and $\begin{smallmatrix} \text{A} \\ | \\ \text{B} \end{smallmatrix}$ have the meaning already indicated, are characterized in that




a compound of general formula IIIa



(IIIa).

in which

R^2 has the meaning indicated in formula I is first hydrogenated and then decarboxylated and oxidized to a compound of general formula II'a




(II'a)

b) or if




stands for



with R^{4b}


meaning a methyl group,

a compound of general formula IIIb




(IIIb).

in which R^2 has the meaning already indicated, is reduced to a compound of general formula II'b




(II'b)

c) or if




stands for



with R^{4c} meaning


an alkyl radical or an alpha,beta-alkenyl radical, both with 2 to 8 carbon atoms, optionally exhibiting several double bonds

a compound of general formula IIIc



(IIIc).


in which R^2 has the meaning already indicated, is reacted with an appropriate Wittig reagent to a compound of general formula II''c



(II'c).

in which R^{4c} represents an alpha,beta-alkenyl radical, with 2-8 carbon atoms, optionally exhibiting several double bonds

the compound of general formula II''c optionally is hydrogenated to a compound of general formula II'c




(II'c).

in which R^{4c} represents an alkyl radical with 2 to 8 carbon atoms,


d) or if



stands for


with R^{4d}

meaning an alpha,beta-alkenyl radical with 2 to 8 carbon atoms, a compound of general formula III c




(IIIc)

is reacted in a modified Wittig reaction with a mixture of triphenylphosphane and tetrahalomethane CHal_4 , and Hal can be bromine and iodine, preferably bromine, to a compound of general formula II''d



and then in a compound of one of general formulas II'a, II'b, II''c, II'c or II''d optionally the 3-methyl ether is cleaved and if the process variant d) is present, after conversion of the compound of general formula II''d or the corresponding 3-hydroxy compound by cleavage of HHal with a base and halogen/hydrogen exchange and optionally after coupling of the resulting H-ethynyl compound with a linear alkylation reagent exhibiting 1 to 6 carbon atoms to a compound of general formula II'd



in which R^{4d} has the meaning already indicated and then optionally the released 3-hydroxy group is again etherified and/or the 17-acetoxy group is saponified, optionally the 3-and


17-hydroxy groups are again esterified and optionally a 3,17-diacyloxy compound thus obtained is selectively saponified to the 3-hydroxy-17-acyloxy compound.

4. Pharmaceutical preparations comprising at least one of the compounds according to claim 1 or claim 2 together with a vehicle usual in galenicals.

5. A method of fertility control of women, comprising administering thereto an effective amount of a compound according to claim 1 or claim 2 either alone or together with a pharmaceutically acceptable diluent or carrier.

6. A method of treatment of estrogen deficiency symptoms of women, comprising administering thereto an effective amount of a compound according to claim 1 or claim 2 either alone or together with a pharmaceutically acceptable diluent or carrier.

7. Compounds of formula IV



in which

R^2 stands for a hydrogen atom or a methyl group and either X means an

alpha-position carbaldehyde group $\text{---} \text{C} \begin{matrix} \text{H} \\ \text{=} \\ \text{O} \end{matrix}$ and

A-B means a C-C single bond as well as E-F means a C-C double bond or C-C single bond,

or

X means a beta-position carbaldehyde group $\text{---} \text{C} \begin{matrix} \text{H} \\ \text{=} \\ \text{O} \end{matrix}$ and

A-B and E-F mean two C-C double bonds or two single bonds.



8. 14alpha,17alpha-Ethanoestradienes as claimed in claim 1 substantially as herein described with reference to the Examples.

5

10


DATED this 13th day of July, 1993.

SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN

By its Patent Attorneys

15 DAVIES COLLISON CAVE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15



INTERNATIONAL SEARCH REPORT

International Application No PCT/DE89/00712

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl.5 C07J 53/00 ; A61K 31/56		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System ¹	Classification Symbols	
Int.Cl.5	C07J ; A61K	
Documentation Searched other than Minimum Documentation to the extent that such documents are included in the fields searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ⁴	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	WO, A, 8801275 (SCHERING AG) 25 February 1988 see the whole document cited in the application -----	1-6
X	Journal of the Chemical Society, Chemical Communication; Nr 6, March 1986, CAMBRIDGE GB; pages 451-453; J.R. Bull et al: "Cycloaddition route to 14 alpha-formylestrone and derived 14 alpha-substituted products" see page 452, compounds 2,3a cited in the application -----	1, 2
P, X	Liebigs Annalen der Chemie Nr 2, February 1989, VCH Verlagsges mbH WEINHEIM DE pages 151-158; S. Scholz et al: "Synthese von 14,17-Überbrückten 11 beta-Arylsteroiden" see the whole document -----	1, 4-6
¹⁰ Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
19 January 1990 (19.01.90)	21 February 1990 (21.02.90)	
International Searching Authority	Signature of Authorized Officer	
European Patent Office		

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

PCT/DE 89/00712

SA 32272

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.


13/02/90

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO-A-8801275	25-02-88	DE-A-	3628189	25-02-88
		AU-A-	7757187	08-03-88
		EP-A-	0318490	07-06-89
		US-A-	4789671	06-12-88
		ZA-A-	8705359	05-02-88

INTERNATIONALER RECHERCHENBERICHT

Internationales Aktenzeichen

PCT/DE 89/00712

I. KLASSEFIZIKATION DES ANMELDUNGSGEGENSTANDS (bei mehreren Klassifikationssymbolen sind alle anzugeben) ⁶		
Nach der Internationalen Patentklassifikation (IPC) oder nach der nationalen Klassifikation und der IPC		
Int.Kl. 5 C07J53/00 ; A61K31/56		
II. RECHERCHIERTE SACHGEBIETE		
Recherchiertes Mindestprüfstoff ⁷		
Klassifikationssystem	Klassifikationssymbole	
Int.Kl. 5	C07J ; A61K	
Recherchierte nicht zum Mindestprüfstoff gehörende Veröffentlichungen, soweit diese unter die recherchierten Sachgebiete fallen ⁸		
III. EINSCHLAGIGE VERÖFFENTLICHUNGEN⁹		
Art. ⁹	Kennzeichnung der Veröffentlichung ¹¹ , soweit erforderlich unter Angabe der maßgeblichen Teile ¹²	Bez. Anspruch Nr. ¹³
X	WO, A, 8801275 (SCHERING AG) 25 Februar 1988 siehe das ganze Dokument (in der Anmeldung erwähnt)	1-6
X	Journal of the Chemical Society, Chemical Communications no. 6, März 1986, CAMBRIDGE GB Seiten 451 - 453; J.R. Bull et al.: "Cycloaddition route to 14alpha-formylestrone and derived 14alpha-substituted products" siehe Seite 452, Verbindungen 2, 3a (in der Anmeldung erwähnt)	1, 2
⁶ Besondere Kategorien von angegebenen Veröffentlichungen¹⁰: "A" Veröffentlichung, die den allgemeinen Stand der Technik definiert, aber nicht als besonders bedeutsam anzusehen ist "E" älteres Dokument, das jedoch erst am oder nach dem internationalen Anmeldedatum veröffentlicht worden ist "L" Veröffentlichung, die geeignet ist, einen Prioritätsanspruch zweifelhaft erscheinen zu lassen, oder durch die das Veröffentlichungsdatum einer anderen im Recherchenbericht genannten Veröffentlichung belegt werden soll oder die aus einem anderen besonderen Grund angegeben ist (wie ausgeführt) "O" Veröffentlichung, die sich auf eine mündliche Offenbarung, eine Benutzung, eine Ausstellung oder andere Maßnahmen bezieht "P" Veröffentlichung, die vor dem internationalen Anmeldedatum, aber nach dem beanspruchten Prioritätsdatum veröffentlicht worden ist "T" Spätere Veröffentlichung, die nach dem internationalen Anmeldedatum oder dem Prioritätsdatum veröffentlicht worden ist und mit der Anmeldung nicht kollidiert, sondern nur zum Verständnis des der Erfindung zugrundeliegenden Prinzips oder der ihr zugrundeliegenden Theorie angegeben ist "X" Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann nicht als neu oder auf erfinderischer Tätigkeit beruhend betrachtet werden "Y" Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann nicht als auf erfinderischer Tätigkeit beruhend betrachtet werden, wenn die Veröffentlichung mit einer oder mehreren anderen Veröffentlichungen dieser Kategorie in Verbindung gebracht wird und diese Verbindung für einen Fachmann naheliegend ist "A" Veröffentlichung, die Mitglied derselben Patentfamilie ist		
IV. BESCHREIBUNG		
Datum des Abschlusses der internationalen Recherche	Absendedatum des internationalen Recherchenberichts	
19. JANUAR 1990	21. 02. 90	
Internationale Recherchenbehörde	Unterschrift des bevollmächtigten Mediensteten	
EUROPAISCHES PATENTAMT	 T.K. WILLIS	

III. EINSCHLAGIGE VERÖFFENTLICHUNGEN (Fortsetzung von Blatt 2)		
Art *	Kennzeichnung der Veröffentlichung, soweit erforderlich unter Angabe der maßgeblichen Teile	Beiz. Anspruch Nr.
P,X	Liebigs Annalen der Chemie no. 2, Februar 1989, VCH Verlagsges. mbH, WEINHEIM DE Seiten. 151 - 158; S. Scholz et al.: "Synthese von 14,17-überbrückten 11beta-Arylsteroiden" siehe das ganze Dokument ---	1, 4-6

ANHANG ZUM INTERNATIONALEN RECHERCHENBERICHT ÜBER DIE INTERNATIONALE PATENTANMELDUNG NR.

PCT/DE 89/00712

SA 32272

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentdokumente angegeben.

Die Angaben über die Familienmitglieder entsprechen dem Stand der Datei des Europäischen Patentamts am 13/02/90.

13/02/90

Im Recherchenbericht angeführtes Patentdokument	Datum der Veröffentlichung	Mitglied(er) der Patentfamilie	Datum der Veröffentlichung	
WO-A-8801275	25-02-88	DE-A-	3628189	25-02-88
		AU-A-	7757187	08-03-88
		EP-A-	0318490	07-06-89
		US-A-	4789671	06-12-88
		ZA-A-	8705359	05-02-88

EPO FORM P003

Für nähere Einzelheiten zu diesem Anhang : siehe Amtsblatt des Europäischen Patentamts, Nr.12/82